Want to see AU:VBS full AI Analyst Report?
VBS Stock Chart & Stats
AU$0.18
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.18
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.46
Previous CloseN/A
Volume32.26K
Average Volume (3M)97.35K
Market Cap
AU$10.80M
Enterprise ValueAU$8.15M
Total Cash (Recent Filing)AU$330.50K
Total Debt (Recent Filing)AU$467.10K
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding61,690,350
10 Day Avg. Volume169,215
30 Day Avg. Volume97,349
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-8.29
Price to Sales (P/S)4.45
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross Margin ProfileConsistently very high gross margins indicate strong unit economics and product-level pricing power. Over the medium term this provides a durable foundation: if operating expenses are controlled or scale improves, margins can translate into sustainable profitability and cash generation.
Modest Absolute Debt LevelModest nominal debt reduces near-term insolvency pressure and interest burden versus highly leveraged peers. This structural cushion improves solvency prospects and gives management more flexibility to prioritize R&D or restructuring without immediate heavy refinancing needs.
Improved Cash Burn In FY2025An improving cash burn rate signals that cost controls or operational efficiencies are taking effect, extending runway. While FCF remains negative, a sustained reduction in burn is a durable operational improvement that lowers near-term external funding reliance.
Bears Say
Sharp Revenue DeclineA ~46% revenue drop is a severe structural headwind that weakens market position and undermines economies of scale. Persistent top-line contraction makes it harder to absorb fixed R&D and SG&A costs, lengthening the timeline to durable profitability or growth.
Consistent Negative Cash GenerationOngoing negative operating and free cash flow means reported losses convert into real cash outflows, forcing repeated external financing. Over months this raises dilution and liquidity risk and limits the company's ability to invest in product development or commercial expansion.
Shareholders' Equity Turned NegativeNegative equity materially weakens the balance sheet, distorting leverage metrics and constraining access to capital markets. This structural deterioration increases the probability of costly financing, covenant pressure, or restructuring if operational performance doesn't improve.
Vectus Biosystems Limited News
VBS FAQ
What was Vectus Biosystems Limited’s price range in the past 12 months?
Vectus Biosystems Limited lowest share price was AU$0.05 and its highest was AU$0.46 in the past 12 months.
What is Vectus Biosystems Limited’s market cap?
Vectus Biosystems Limited’s market cap is AU$10.80M.
When is Vectus Biosystems Limited’s upcoming earnings report date?
Vectus Biosystems Limited’s upcoming earnings report date is Sep 02, 2026 which is in 46 days.
How were Vectus Biosystems Limited’s earnings last quarter?
Vectus Biosystems Limited released its earnings results on Feb 26, 2026. The company reported -AU$0.014 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.014.
Is Vectus Biosystems Limited overvalued?
According to Wall Street analysts Vectus Biosystems Limited’s price is currently Overvalued.
Does Vectus Biosystems Limited pay dividends?
Vectus Biosystems Limited does not currently pay dividends.
What is Vectus Biosystems Limited’s EPS estimate?
Vectus Biosystems Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vectus Biosystems Limited have?
Vectus Biosystems Limited has 61,690,350 shares outstanding.
What happened to Vectus Biosystems Limited’s price movement after its last earnings report?
Vectus Biosystems Limited reported an EPS of -AU$0.014 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.571%.
Which hedge fund is a major shareholder of Vectus Biosystems Limited?
Currently, no hedge funds are holding shares in AU:VBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vectus Biosystems Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
143.75%
12-Months-Change
Fundamentals
Return on Equity
265.12%
Trailing 12-Months
Asset Growth
-62.59%
Trailing 12-Months
Company Description
Vectus Biosystems Limited
Vectus Biosystems Limited, an Australian medical research and development firm, specializes in devising therapies for fibrotic conditions and hypertension. Its pharmaceutical pipeline addresses ailments affecting the heart, kidneys, liver, and lungs. The company's leading experimental drug, VB0004, aims to counter the degradation of functional tissue resulting from fibrosis, scarring, and elevated blood pressure. Furthermore, Vectus intends to advance treatments for hepatic fibrotic diseases, such as non-alcoholic steatohepatitis, and various pulmonary fibrotic disorders. Beyond its therapeutic endeavors, the company also provides AccuCal and RealCount software, tools engineered to enhance the swiftness and precision of DNA and RNA quantification in laboratory settings. Established in 2005, Vectus Biosystems is headquartered in Rosebery, Australia.
Technical Analysis
Acrux
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―